K36 Therapeutics

06/03/2026

Did you know?
About 15-20% of multiple myeloma patients have a genetic abnormality called t(4;14), which leads to increased activity of the NSD2/MMSET protein.

Researchers are studying investigational therapies designed to target the biology driving this subtype. Clinical trials continue to play an important role in advancing treatment options for patients with high-risk myeloma.

If you have t(4;14) myeloma, ask your doctor about your cytogenetic profile and whether a clinical trial may be right for you. Knowledge is power. 💙
https://www.k36tx.com/our-clinical-trials

06/02/2026

🩸 Not all multiple myeloma is the same.
And neither should treatment be.
For patients with t(4;14) relapsed/refractory multiple myeloma, a high-risk subtype driven by NSD2 biology, new approaches are urgently needed.
K36 Therapeutics recognizes the patients, caregivers, physicians, and researchers working to change what is possible.
We are proud to advance KTX-1001 (gintemetostat), a first-in-class, oral NSD2 inhibitor being studied in rrMM with the goal of targeting disease at its biological source.
The K-36 MMSET Phase 1B study is designed to address a biologically defined high-risk population through targeted inhibition of NSD2. The trial is now enrolling expansion cohorts combining gintemetostat with established and emerging standard-of-care regimens, including:
Gintemetostat + carfilzomib + dexamethasone
Gintemetostat + pomalidomide + dexamethasone
Gintemetostat + mezigdomide + dexamethasone
Because blood cancer research is not just about science.
It is about giving patients more time, more options, and more hope.
💙 Learn more about our MMSET clinical trial: https://www.k36tx.com/our-clinical-trials

A new oral drug could offer hope for people facing one of the most aggressive forms of multiple myeloma.

Some people with multiple myeloma have a genetic change called t(4;14). This mutation is associated with faster disease progression and fewer treatment options over time. Until now, there have been no therapies that directly target this genetic driver, leaving many patients with limited options after relapse.
At the 2025 American Society of Hematology Annual Meeting, IMF's Scientific Advisory Board member Dr. Saad Usmani shared updated results from a Phase 1 clinical trial studying KTX-1001, a first-in-class oral therapy designed for high-risk multiple myeloma. KTX-1001 was developed to specifically shut down the activity of the protein that fuels cancer growth in myeloma with the t(4;14) mutation. This makes it the first drug designed to target this high-risk driver at its source.

Even in this heavily treated group, researchers observed encouraging signs of anti-myeloma activity. About 40 percent of participants achieved disease control, meaning their cancer responded or remained stable, and some responses lasted a year or longer.

Because these early results are encouraging, the research is now moving forward to study KTX-1001 in combination with other therapies, including carfilzomib and the investigational drug mezigdomide. These next steps will help determine how this therapy may strengthen existing treatments and improve outcomes for people with high-risk disease.

For people living with relapsed or refractory multiple myeloma, especially those with the t(4;14) mutation, treatment options often become more limited over time. A targeted oral therapy that addresses the genetic driver of the disease could represent an important step forward and help people live longer.

This is the type of research the International Myeloma Foundation champions through our Scientific Advisory Board, the International Myeloma Working Group, and in close partnership with leaders like Dr. Saad Usmani. Together, we help guide the science that shapes care for people with myeloma worldwide.

To learn more about the latest research directly from the IMF Scientific Advisory Board, visit: https://mmsm.link/4boNwxd

06/02/2026

The energy at McCormick Place is real. Advances in hashtag and hashtag hashtag continue to show how quickly oncology is moving toward more personalized treatment approaches.

At K36 Therapeutics, Inc. we are excited about the progress of KTX-2001 in mCRPC and KTX-1001 (gintemetostat) MMSET dose expansion combination cohorts in myeloma.

Most meaningful has been connecting with investigators, CRO partners, patients, and advocacy groups who continue to push the field forward.

There is still important work ahead to deliver deeper, more durable responses with manageable safety, and we are energized to contribute with our first-in-class NSD2 inhibitor programs.

05/29/2026

🧬 Not all multiple myeloma is the same. Do you know your Myeloma?

Cytogenetic testing, FISH (Fluorescence In Situ Hybridization) is a laboratory test used to detect specific genetic changes, such as gene amplifications, deletions, or translocations, within cancer cells. It fluorescently labeled DNA "probes" that light up under a microscope to reveal chromosomal abnormalities)

FISH test helps identify high-risk features like t(4;14) that can influence prognosis, treatment decisions, and eligibility for clinical trials. For patients with t(4;14), knowing your status may unlock access to investigational options designed specifically for this biology. https://www.k36tx.com/our-clinical-trials

Knowing your cytogenetics is knowledge and knowledge opens opportunities. This Day, we’re raising awareness of why testing matters.

To learn more:
https://healthtree.org/myeloma/community/articles/what-is-a-fish-test-in-multiple-myeloma

05/28/2026

🩸 Today is World Blood Cancer Day
Not all multiple myeloma is the same. And neither should treatment be.
For patients with t(4;14) relapsed/refractory multiple myeloma, a high-risk subtype driven by NSD2 biology, new approaches are urgently needed.

This , K36 Therapeutics recognizes the patients, caregivers, physicians, and researchers working to change what is possible.
We are proud to advance KTX-1001 (gintemetostat), a first-in-class, oral NSD2 inhibitor being studied in rrMM with the goal of targeting disease at its biological source.

The K-36 MMSET Phase 1B study is designed to address a biologically defined high-risk population through targeted inhibition of NSD2. The trial is now enrolling expansion cohorts combining gintemetostat with established and emerging investigational and standard-of-care regimens, including:
• Gintemetostat + carfilzomib + dexamethasone
• Gintemetostat + pomalidomide + dexamethasone
• Gintemetostat + mezigdomide + dexamethasone

Because blood cancer research is not just about science. It is about giving patients more time, more options, and more hope.

🔬💙🔬🧬 Learn more about our MMSET clinical trial: https://www.k36tx.com/our-clinical-trials

05/24/2026

This Memorial Day, we pause to honor and remember the brave men and women who made the ultimate sacrifice in service to our country. We are grateful for their courage, dedication, and the freedoms they helped protect. 🇺🇸

05/21/2026

Congratulations to Dr. Saad Usmani on receiving the Jean-Luc Harousseau Award at COMy 2026 in Paris.

This recognition carries special meaning in the myeloma community. Named after Prof. Jean-Luc Harousseau, one of the pioneers who helped shape modern myeloma care and clinical research, the award honors exceptional contributions to advancing the field and improving outcomes for patients.

Dr. Usmani’s leadership, scientific rigor, and commitment to patients have helped move myeloma treatment forward across high-risk disease, innovative therapies, and clinical trial development. His work continues to influence how we think about treatment possibilities and the future of care.

At K36 Therapeutics, we are grateful for investigators and scientific leaders who challenge the field to keep pushing boundaries for patients facing multiple myeloma.
Congratulations, Saad, on this well-deserved recognition.

05/20/2026

Today is 💙
Clinical trials are often talked about as science, data, and innovation. And they are. But they are also people.
At K36 Therapeutics, we are reminded every day that clinical research only moves forward because people choose to make it possible.

To the patients participating in our KTX-1001 and KTX-2001 studies, thank you. Thank you for your time, your commitment to study visits, your trust, and your willingness to participate in research that may help future patients.

To caregivers and families, thank you for the rides to appointments, the medication reminders, the encouragement, and the steady support that often happens quietly behind the scenes.

To doctors, nurses, and study coordinators, thank you for guiding patients through difficult decisions and helping them navigate investigational treatment options with care and compassion.
And to the researchers, clinical teams, site staff, and partners working through protocols, samples, data, and countless details to bring new therapies forward, thank you for the persistence and purpose you bring every day.

In and , we continue working to better understand the biology driving disease and explore new investigational approaches for patients who need more options.

Today, we celebrate everyone who helps turn clinical trials into reality.

To learn more about Clinical Trials https://www.k36tx.com/our-clinical-trials

05/17/2026

brought together many of the leading investigators advancing multiple myeloma research across Europe and the US, including investigators participating in the K36 Therapeutics MMSET clinical trial.

While much of the congress focused on the remarkable progress with CAR-T and bispecific therapies, an important theme continued to emerge: patients still need novel therapies capable of delivering durable responses with manageable safety profiles.

As Dr. Xavier Leleu noted:
“Unmet medical need remains where we need novel agents to achieve both durable responses and manageable safety profile.”

At K36 Therapeutics, we are encouraged by the growing global focus on precision approaches targeting the biology driving high-risk disease, including NSD2/MMSET biology in t(4;14) multiple myeloma.

Our clinical trial evaluating the first-in-class NSD2 inhibitor KTX-1001 (gintemetostat) is currently open across France, Spain, Canada, and the United States.

Clinical trial information:
https://clinicaltrials.gov/study/NCT05651932

05/14/2026

As we approach National Clinical Trials Day next week, we want to recognize the people behind every study who help turn scientific ideas into real patient impact.

Clinical trials do not happen by accident. They happen because dedicated teams work every day to move research forward with urgency, precision, and heart. To the clinical operations teams coordinating every detail behind the scenes.

To study coordinators and research nurses who guide patients through every visit and become trusted partners in their care.

To investigators and physicians who bring innovative studies to their patients and communities.

To data managers, regulatory teams, safety teams, CRO partners, pharmacists, laboratory staff, and site budget & contracts personnel who keep studies running and patients safe.

To caregivers and families supporting loved ones through the uncertainty of treatment and research participation.

And most importantly, to the patients who choose to participate in clinical trials and help advance science for future generations.
Thank you.

At K36 Therapeutics, we are proud to work alongside so many passionate people committed to advancing new therapies in multiple myeloma and prostate cancer.

Learn about our clinical trials: https://www.k36tx.com/our-clinical-trials

Every protocol, every data point, every patient visit represents hope and the collective effort of people who refuse to stop pushing science forward.